Year All2024202320222021202020192018201720162015201420132012201120102007 02.27.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. Read More 02.16.17 Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017 WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More 02.09.17 Syndax Appoints Richard P. Shea as Chief Financial Officer WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Read More 01.31.17 Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board Adds additional scientific and clinical expertise in critical immune-regulated pathways therapeutically relevant for oncology Read More 01.05.17 Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Read More 12.14.16 Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research Read More 11.21.16 Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More 11.10.16 Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanoma Phase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More 11.08.16 Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster presentations at the Read More 10.28.16 Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016 WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More 09.06.16 Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in four upcoming investor conferences. Read More 08.09.16 Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody Progressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma Initiated ENCORE 602 for TNBC in collaboration with Genentech in June 2016 WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ("Syndax," Read More
02.27.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. Read More
02.16.17 Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017 WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More
02.09.17 Syndax Appoints Richard P. Shea as Chief Financial Officer WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Read More
01.31.17 Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board Adds additional scientific and clinical expertise in critical immune-regulated pathways therapeutically relevant for oncology Read More
01.05.17 Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Read More
12.14.16 Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research Read More
11.21.16 Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More
11.10.16 Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanoma Phase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More
11.08.16 Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster presentations at the Read More
10.28.16 Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016 WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More
09.06.16 Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in four upcoming investor conferences. Read More
08.09.16 Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody Progressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma Initiated ENCORE 602 for TNBC in collaboration with Genentech in June 2016 WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ("Syndax," Read More